Improving global healthcare access thanks to a continuous and sustainable mRNA manufacturing solution.

Dillico was cofounded by senior industry experts for the purpose of developing and marketing a unique integrated and digitalized all-scale-range mRNA drug product manufacturing solution.

With its continuous and automated mRNA-LNP manufacturing system, Dillico is revolutionizing the landscape of the biopharma industry.

Our proprietary flow technology and unique production process allow for the production of mRNA vaccines and therapies at any scale, from discovery to commercial manufacturing, using the same piece of equipment. This continuous all-scale solution significantly reduces the time and effort that goes into development, as well as offering unmatched flexibility in terms of production capacity.


Christophe Bonneville

CEO & co-founder

Christophe Bonneville leads the company’s global strategy with a vision that champions the adoption of Pharma 4.0 solutions on the global pharma market. Previously, he was co-founder and CEO of Resolution Spectra, which was acquired by Merck Millipore in 2020 for its bioprocess monitoring solution. He has also held Business Unit Manager and Program Manager roles at various companies in the space industry. He holds a PhD in Physics, specifically in the field of Instrumental Optics, and is a graduate of Ecole Centrale de Marseille in France.

Flora Binder

Chief Development Officer & co-founder

Flora leads the process development of Dillico’s technology to provide robust, fully digitized and optimized manufacturing solutions. Previously, she has been working at Moderna and Biogen in Manufacturing Science, she was responsible for process technology transfer and validation activities. She received her Masters Degree in Biotechnology from Grenoble Alpes University.

Emmanuel Gaud

Chief Operating officer & co-founder

Emmanuel Gaud acts as a Chief Operating Officer. After completion of AgroParis Tech School, Emmanuel has been working with passion in the Life Science Industries. For 23 years, he has built process system design addressing the food, cosmetics, pharmaceutical and biotech market. Emmanuel is now putting his strength working with Dillico to bring to life the manufacturing solution.

Daniel Marquez Martin

Process Scientist

Jean de Seze

Development Scientist

Lucas Audoui

Senior Process Equipment Engineer

Brice Pawelec

Process Scientist Intern


Yves-Loic Martin

Dr Yves-Loic Martin graduated from École Polytechnique in Paris, France, and holds a Master’s Degree in Applied Mathematics from University Paris VI and a PhD in Chemometrics from Institut National Paris Grignon. Yves-Loic is a co-founder of Eurofins and mainly assumed the role of Chief Technology Officer, where he was instrumental in setting up the Group’s IT infrastructure and solutions as well as its knowledge management practices. Since 2022, Yves-Loic is an active Business Angel and early-stage investor focused on Deeptech European startups.

Guillaume Leroy

Guillaume Leroy  is the founder of Global Life Sciences Advisory, advising board of directors, executive teams and International Organizations. He is CEO of EdJen Biotech and member of the board of ICW Healthcare Ventures. He started his career at Sanofi Pasteur in Brazil and then took on growing P&L accountability. Returning to France in 2011, he experienced the entire development of the first Dengue vaccine by developing a unique dedicated cross functional organization. He then took the full accountability of the commercial operations of the Sanofi group in France before being promoted President of Sanofi France.


Dillico moved

We are thrilled to announce that we are transitioning our site to a new location. As of now, we'll be located at Inovallée, Meylan; near our previous office in Grenoble. We’re heading [...]

18 October 2023|

Dillico Grand Prix i-Lab 2023

Dillico Grand Prix i-Lab 2023 (English version below) Nous sommes honorés d'avoir été choisis parmi de nombreux candidats exceptionnels, comme lauréat du Grand prix i-Lab 2023 ! Ce prix revêt une importance particulière [...]

6 July 2023|


We are pleased to welcome you to our new website. Until now, Dillico has remained very discreet, focusing on exchanges with the main players in the mRNA field - we are now [...]

15 January 2023|


They trust us